Cargando…

Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19

Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged as a risk factor for chronic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Duployez, Nicolas, Demonchy, Jordane, Berthon, Céline, Goutay, Julien, Caplan, Morgan, Moreau, Anne-Sophie, Bignon, Anne, Marceau-Renaut, Alice, Garrigue, Delphine, Raczkiewicz, Imelda, Geffroy, Sandrine, Bucci, Maxime, Alidjinou, Kazali, Demaret, Julie, Labalette, Myriam, Brousseau, Thierry, Dupont, Annabelle, Rauch, Antoine, Poissy, Julien, Susen, Sophie, Preudhomme, Claude, Quesnel, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409316/
https://www.ncbi.nlm.nih.gov/pubmed/32708264
http://dx.doi.org/10.3390/cancers12071992
Descripción
Sumario:Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged as a risk factor for chronic inflammatory background and subsequent aging-associated diseases. The purpose of this study was to identify biological factors (particularly leukocyte subtypes and inflammatory markers) associated with a risk of clinical deterioration (i.e., orotracheal intubation (OTI)) and to determine whether CH was likely to influence clinical and biological behavior in patients with severe COVID-19 requiring hospitalization. Here, we describe clinical and biological features, including the screening of CHIP mutants in a well-annotated cohort of 122 hospitalized patients with a laboratory-confirmed diagnosis of COVID-19 (55% requiring OTI). We showed that elevated white blood cell counts, especially neutrophils and high C-reactive protein (CRP) levels at admission, were associated with an increased requirement of OTI. We noticed a high prevalence of CH (25%, 38%, 56%, and 82% of patients aged <60 years, 60–70 years, 70–80 years, and >80 years) compared to a retrospective cohort of patients free of hematological malignancy explored with the same pipelines (10%, 21%, 37%, and 44%). However, the existence of CH did not significantly impact clinical outcome, including OTI or death, and did not correlate with other laboratory findings.